Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

PHASE1TerminatedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

May 7, 2025

Study Completion Date

June 2, 2025

Conditions
Stomach NeoplasmGastrointestinal NeoplasmsDigestive System NeoplasmNeoplasms by SiteNeoplasms
Interventions
DRUG

EO-3021

Anti-Claudin 18.2 antibody drug conjugate

DRUG

Ramucirumab (CYRAMZA®)

VEGFR2 inhibitor

DRUG

Dostarlimab

anti-PD-1 antibody

Trial Locations (20)

10065

Memorial Sloan Kettering Cancer Center, New York

20007

Georgetown University, Washington D.C.

20016

Johns Hopkins University - Sibley Memorial Hospital, Washington D.C.

28204

Atrium Health/Wake Forest University, Charlotte

32224

Mayo Clinic, Jacksonville

32827

Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando

37203

Sarah Cannon Research Institute, Nashville

48202

Henry Ford Cancer, Detroit

49546

START Midwest, Grand Rapids

53792

UW Carbone Cancer Center - Cancer Connect, Madison

55905

Mayo Clinic, Rochester

75230

Mary Crowley Cancer Research, Dallas

77030

MD Anderson Cancer Center, Houston

85054

Mayo Clinic, Phoenix

91010

City of Hope, Duarte

06519

Yale - Smilow Cancer Hospital, New Haven

277-8577

National Cancer Center Hospital East, Kashiwa-shi

104-0045

National Cancer Center Hospital, Chuo Ku

Unknown

Samsung Medical Center, Seoul

Yonsei University, Seoul

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

CSPC Pharmaceutical Group Limited

INDUSTRY

lead

Elevation Oncology

INDUSTRY

NCT05980416 - Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2 | Biotech Hunter | Biotech Hunter